Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
RESEARCH TOOLSreports
Larimar Therapeutics (LRMR) Stock Price & Analysis
360 Followers
LRMR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.18 - $13.68
Previous Close$9.32
Volume316.58K
Average Volume (3M)582.91K
Market Cap
$594.63M
Enterprise Value$372.68M
Total Cash (Recent Filing)$227.30M
Total Debt (Recent Filing)$5.34M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 08, 2024EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding63,802,017
10 Day Avg. Volume425,539
30 Day Avg. Volume582,913
Standard Deviation0.26
R-Squared0.03
Alpha0.00413
Financial Highlights & Ratios
Price to Book (P/B)6.35
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.67
Forecast
1Y Price Target
$25.00Price Target Upside168.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Larimar Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceNomlabofusp improved frataxin levels in skin punch biopsies from a mean of ~13% at baseline to ~46% at Day 14 with daily 50mg treatment.
Financial PositionThe plan for BLA submission is bolstered by the recent completion of a $172.5M equity raise, bringing Larimar’s cash balance to ~$259M and well beyond a potential 2026 approval.
Regulatory ApprovalAcceptance into the START pilot program reduces regulatory risk by allowing deeper FDA involvement in generating data and planning studies.
Bears Say
Clinical Trial ConcernsLess pronounced frataxin increases in buccal cells and lower levels at a 50 mg dose in Phase 2 vs. Phase 1 are potential concerns.
Financial PerformanceLarimar reported a net loss of $14.7 million, significantly higher than the net loss of $6.5 million reported previously.
Regulatory IssuesThe FDA placed a clinical hold on nomlabofusp due to mortalities at the highest dose levels in a non-human primate study.
---
Ownership Overview
50.76% Insiders
7.20% Mutual Funds
8.32% Other Institutional Investors
33.72% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $2.18 and its highest was $13.68 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Aug 08, 2024 which is in 18 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on May 09, 2024. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.244 by -$0.026.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -$0.31.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 63,802,017 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.244. Following the earnings report the stock price went down -0.758%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Among the largest hedge funds holding Larimar Therapeutics, Inc.’s share is Deerfield Management Company, LP. It holds Larimar Therapeutics, Inc.’s shares valued at 161M.
---
Larimar Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (168.24% Upside)
$25.00 (168.24% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 11.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $500.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
192.16%
12-Months-Change
Fundamentals
Return on Equity
-26.75%
Trailing 12-Months
Asset Growth
108.74%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.
---
LRMR Stock 12 Month Forecast
Average Price Target
$25.00
▲(168.24% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
Viking Therapeutics
―
Fate Therapeutics
―
Best Analysts Covering LRMR
1 Year
1 Year Success Rate
15/20 ratings generated profit
1 Year Average Return
+51.01%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +51.01% per trade.
---